• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替代糖作为干粉吸入剂的潜在载体。

Alternative sugars as potential carriers for dry powder inhalations.

作者信息

Steckel Hartwig, Bolzen Nina

机构信息

Department of Pharmaceutics and Biopharmaceutics, Christian Albrecht University Kiel, Gutenbergstrasse 76, Kiel 24118, Germany.

出版信息

Int J Pharm. 2004 Feb 11;270(1-2):297-306. doi: 10.1016/j.ijpharm.2003.10.039.

DOI:10.1016/j.ijpharm.2003.10.039
PMID:14726144
Abstract

Most dry powder inhaler (DPI) formulations rely on lactose monohydrate as a carrier in the drug powder blends. However, lactose cannot be used for compounds that interact with the reducing sugar function of the lactose, such as formoterol, budesonide or peptides and proteins. In this study, alternative carriers like mannitol, glucose, sorbitol, maltitol and xylitol have therefore been evaluated for their potential use in DPI formulations. Raw materials were characterised physico-chemically and blends with the model drug substance budesonide were tested with respect to the aerosolization behaviour of the powders. It was found out that similarly to the problems known for lactose monohydrate, such as supplier variability, variability between different qualities of one supplier, the same difficulties apply to the alternative carriers investigated. Different sources and qualities of mannitol led to significant differences in the fine particle fraction (FPF), varying from 15 to 50% for two different qualities of mannitol. Similar observations were made for the other carrier materials studied. Also, the influence of conditioning the raw material at different relative humidity was found to have substantial influence on the performance of drug/carrier blends which is characterised by a strong decrease in the FPF. In summary, mannitol showed potential as a drug carrier to be used in DPIs whereas the more hygroscopic sugars only showed poor dispersibility.

摘要

大多数干粉吸入器(DPI)制剂在药物粉末混合物中依赖一水乳糖作为载体。然而,乳糖不能用于与乳糖的还原糖功能相互作用的化合物,如福莫特罗、布地奈德或肽和蛋白质。因此,在本研究中,对甘露醇、葡萄糖、山梨醇、麦芽糖醇和木糖醇等替代载体在DPI制剂中的潜在用途进行了评估。对原材料进行了物理化学表征,并针对粉末的雾化行为测试了与模型药物布地奈德的混合物。结果发现,与一水乳糖已知的问题类似,如供应商的变异性、同一供应商不同质量之间的变异性,同样的困难也适用于所研究的替代载体。不同来源和质量的甘露醇导致细颗粒分数(FPF)存在显著差异,两种不同质量的甘露醇的细颗粒分数从15%到50%不等。对所研究的其他载体材料也有类似的观察结果。此外,发现在不同相对湿度下对原材料进行预处理对药物/载体混合物的性能有重大影响,其特征是细颗粒分数大幅下降。总之,甘露醇显示出作为药物载体用于干粉吸入器的潜力,而吸湿性更强的糖类仅显示出较差的分散性。

相似文献

1
Alternative sugars as potential carriers for dry powder inhalations.替代糖作为干粉吸入剂的潜在载体。
Int J Pharm. 2004 Feb 11;270(1-2):297-306. doi: 10.1016/j.ijpharm.2003.10.039.
2
Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.湿度引起的含有不同载体的干粉气雾剂制剂空气动力学性质的变化。
Int J Pharm. 2007 Mar 21;333(1-2):45-55. doi: 10.1016/j.ijpharm.2006.09.048. Epub 2006 Oct 1.
3
Influence of carrier on the performance of dry powder inhalers.载体对干粉吸入器性能的影响。
Int J Pharm. 2007 Apr 4;334(1-2):85-91. doi: 10.1016/j.ijpharm.2006.10.028. Epub 2006 Oct 21.
4
Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide.探讨替代糖作为布地奈德干粉制剂潜在载体的研究。
Bioimpacts. 2011;1(2):105-11. doi: 10.5681/bi.2011.014. Epub 2011 Aug 5.
5
Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.基于干细胞因子(SCF)工程化颗粒的乳糖混合物在被动干粉吸入器中的评估。
Int J Pharm. 2004 Aug 20;281(1-2):55-66. doi: 10.1016/j.ijpharm.2004.05.029.
6
Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.以具有定制表面形态的喷雾干燥甘露醇为载体和硫酸沙丁胺醇的干粉吸入器性能。
Int J Pharm. 2017 May 30;524(1-2):351-363. doi: 10.1016/j.ijpharm.2017.03.055. Epub 2017 Mar 24.
7
Budesonide dry powder for inhalation: effects of leucine and mannitol on the efficiency of delivery.布地奈德吸入用干粉:亮氨酸和甘露醇对递送效率的影响。
Drug Deliv. 2014 Sep;21(6):397-405. doi: 10.3109/10717544.2013.868555. Epub 2014 Jan 8.
8
Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.干粉吸入剂中的空气分级器技术(ACT) 第4部分。Novolizer多剂量干粉吸入器中空气分级器技术的性能。
Int J Pharm. 2006 Mar 9;310(1-2):81-9. doi: 10.1016/j.ijpharm.2005.11.029. Epub 2006 Jan 25.
9
The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.含甘露醇赋形剂的干粉中沙丁胺醇的增强气溶胶性能。
Int J Pharm. 2010 Jun 15;392(1-2):178-88. doi: 10.1016/j.ijpharm.2010.03.057. Epub 2010 Apr 2.
10
Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.用于预测干粉吸入性能的胶体探针原子力显微镜的内聚-粘附平衡方法与反相气相色谱法测量汉森部分溶解度参数的比较。
Int J Pharm. 2016 Jul 25;509(1-2):419-430. doi: 10.1016/j.ijpharm.2016.06.002. Epub 2016 Jun 2.

引用本文的文献

1
Dry Powder Inhalers for Delivery of Synthetic Biomolecules.用于递送合成生物分子的干粉吸入器。
Pharmaceuticals (Basel). 2025 Jan 27;18(2):175. doi: 10.3390/ph18020175.
2
Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.吸入式口服药品的扩大生产及批准后变更:科学与监管考量
J Aerosol Med Pulm Drug Deliv. 2025 Apr;38(2):39-63. doi: 10.1089/jamp.2024.0036. Epub 2024 Dec 9.
3
Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.干粉吸入器中使用的不同载体:其颗粒特性
J Aerosol Med Pulm Drug Deliv. 2024 Dec;37(6):307-327. doi: 10.1089/jamp.2023.0029. Epub 2024 Aug 9.
4
Enhancing bioavailability of natural extracts for nutritional applications through dry powder inhalers (DPI) spray drying: technological advancements and future directions.通过干粉吸入器喷雾干燥提高天然提取物在营养应用中的生物利用度:技术进展与未来方向。
Front Nutr. 2023 Jul 5;10:1190912. doi: 10.3389/fnut.2023.1190912. eCollection 2023.
5
Nano-adjuvanted dry powder vaccine for the mucosal immunization against airways pathogens.用于呼吸道病原体黏膜免疫的纳米佐剂干粉疫苗。
Front Vet Sci. 2023 Mar 14;10:1116722. doi: 10.3389/fvets.2023.1116722. eCollection 2023.
6
Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.干粉吸入器设计与开发的进展及其对仿制药开发的潜在影响。
Pharmaceutics. 2022 Nov 17;14(11):2495. doi: 10.3390/pharmaceutics14112495.
7
A CFD-DEM investigation of powder transport and aerosolization in ELLIPTA® dry powder inhaler.ELLIPTA® 干粉吸入器中粉末输送和气溶胶化的计算流体动力学-离散单元法研究
Powder Technol. 2022 Sep;409. doi: 10.1016/j.powtec.2022.117817.
8
Production of Inhalable Ultra-Small Particles for Delivery of Anti-Inflammation Medicine via a Table-Top Microdevice.通过桌面微型装置生产用于递送抗炎药物的可吸入超小颗粒。
Micromachines (Basel). 2022 Aug 25;13(9):1382. doi: 10.3390/mi13091382.
9
Design and Characterization of Atorvastatin Dry Powder Formulation as a potential Lung Cancer Treatment.阿托伐他汀干粉制剂作为潜在肺癌治疗药物的设计与表征
Saudi Pharm J. 2021 Dec;29(12):1449-1457. doi: 10.1016/j.jsps.2021.11.002. Epub 2021 Nov 11.
10
Effects of dose loading conditions and device geometry on the transport and aerosolization in dry powder inhalers: A simulation study.剂量加载条件和装置几何形状对干粉吸入器中药物输送和气溶胶化的影响:一项模拟研究。
Int J Pharm. 2021 Dec 15;610:121219. doi: 10.1016/j.ijpharm.2021.121219. Epub 2021 Oct 24.